Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

By F. Fossella, R. Devore, R. Kerr, J. Crawford, R. Natale, F. Dunphy, L. Kalman, Vincent A. Miller, J. S. Lee, M. Moore and 7 more. 2000

1,280 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/11d564996a9c6b1a0e68dac10f25c9c725848fca

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Kerr
2. M. Hellmann

Citations in the corpus

• Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer (2015, neutral): “Decreased appetite 30 (10) 0 42 (16) 3 (1)”
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, methodology): “Docetaxel has shown improved efficacy compared with BSC in randomised trials with a significant improvement in OS in the TAX 320 trial for those patients who received docetaxel at a dose of 75 mg/m(2) every 3 weeks [152, 153].”